Title: Methylated SEPT9 combined with AFP and PIVKA-II is effective for the detection of
HCC in high-risk population
Version: 0 Date: 11 Feb 2023
Reviewer:  Jin-Wook Kim
Reviewer's report:
This work assessed the diagnostic performance of methylated SEPT9 for HCC.
1. This study is case-control: screening performance cannot be deduced from this work.
2. What is the proportion of comorbid cirrhosis in HCC?
3. Liver function may affects the diagnostic performance of HCC tumor markers: present
albumin, bilirubin, prothrombin time, platelet counts data.
4. comparison of sensitivity / specificity may not be appropriate for comparing tumor marker
performances: present comparison of AUROC with p values: I guess the AUC did not seem to
differ between the markers.
5. Include AUROC comparison between AFP and AFP+mSEPT9.
6. As indicated in discussion, effect of viral markers need to be elucidated.
Title: Methylated SEPT9 combined with AFP and PIVKA-II is effective for the detection of
HCC in high-risk population
Version: 0 Date: 11 Feb 2023
Reviewer:  Jin-Wook Kim
Reviewer's report:
This work assessed the diagnostic performance of methylated SEPT9 for HCC.
1. This study is case-control: screening performance cannot be deduced from this work.
2. What is the proportion of comorbid cirrhosis in HCC?
3. Liver function may affects the diagnostic performance of HCC tumor markers: present
albumin, bilirubin, prothrombin time, platelet counts data.
4. comparison of sensitivity / specificity may not be appropriate for comparing tumor marker
performances: present comparison of AUROC with p values: I guess the AUC did not seem to
differ between the markers.
5. Include AUROC comparison between AFP and AFP+mSEPT9.
6. As indicated in discussion, effect of viral markers need to be elucidated.
Please review this paper.
user
Title: Methylated SEPT9 combined with AFP and PIVKA-II is effective for the detection of
HCC in high-risk population
Version: 0 Date: 11 Feb 2023
Reviewer:  Jin-Wook Kim
Reviewer's report:
This work assessed the diagnostic performance of methylated SEPT9 for HCC.
1. This study is case-control: screening performance cannot be deduced from this work.
2. What is the proportion of comorbid cirrhosis in HCC?
3. Liver function may affects the diagnostic performance of HCC tumor markers: present
albumin, bilirubin, prothrombin time, platelet counts data.
4. comparison of sensitivity / specificity may not be appropriate for comparing tumor marker
performances: present comparison of AUROC with p values: I guess the AUC did not seem to
differ between the markers.
5. Include AUROC comparison between AFP and AFP+mSEPT9.
6. As indicated in discussion, effect of viral markers need to be elucidated.
assistant